phosphoserine has been researched along with Cardiomyopathy, Hypertrophic Obstructive in 2 studies
Phosphoserine: The phosphoric acid ester of serine.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Leary, TS | 1 |
| Snyder, J | 1 |
| Sadayappan, S | 1 |
| Day, SM | 1 |
| Previs, MJ | 1 |
| Fu, Y | 1 |
| Westenbroek, RE | 1 |
| Scheuer, T | 1 |
| Catterall, WA | 1 |
2 other studies available for phosphoserine and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.
Topics: Actin Cytoskeleton; Actomyosin; Adult; Alleles; Animals; Cardiomyopathy, Hypertrophic; Carrier Prote | 2019 |
Basal and β-adrenergic regulation of the cardiac calcium channel CaV1.2 requires phosphorylation of serine 1700.
Topics: Adaptation, Physiological; Adrenergic beta-Agonists; Amino Acid Substitution; Animals; Arrhythmias, | 2014 |